Management Team

jonas (2)

Jonas Hansson

Born 1974. Chief Executive Officer since 2012.

  • Education: M.Sc. in pharmacy, Uppsala University and MBA, Stockholm School of Economics.
  • Other current assignments: Venture Partner of HealthCap VI GP SA and HealthCap VII GP SA.
  • Previous assignments (last five years): Board member of ReVENT Medical, Inc.
  • Holdings in the Company: 50,000 shares and 390,000 stock options.

_W8A8386LEVFF

Carl Bjartmar

Born 1963. Chief Medical Officer since 2015.

  • Education: MD and Ph.D. in neuroscience, University of Linköping.
  • Other current assignments: –
  • Previous assignments (last five years): Senior medical director of Sanofi-Aventis AB and Genzyme AB.
  • Holdings in the Company: 3,500 shares and 150,500 stock options.

_W8A8392LEVFF

Susan Flint

Born 1951. Vice President and Head of Clinical Operations since 2014.

  • Education: MS in pharmacology, Northeastern University, Boston and BS in biology, Bridgewater State College.
  • Other current assignments: –
  • Previous assignments (last five years): Executive director and Head of Clinical Operations of Oxyrane Ltd.
  • Holdings in the Company: 125,000 stock options.

_W8A8325LEVFF

Anders Martin-Löf

Born 1971. Chief Financial Officer since 2015.

  • Education: BA, business administration and economics, Stockholm University and M.Sc., Engineering Physics, the Royal Institute of Technology, Stockholm.
  • Other current assignments: –
  • Previous assignments (last five years): Board member of ScienceCap Stockholm AB, CFO of Extenda AB and CFO and Director of Marketing of RaySearch Laboratories AB (publ).
  • Holdings in the Company: 1,400 shares and 170,000 stock options.

_W8A8338LEVFF

Lars Olsson

Born 1967. Vice President of Chemistry, Manufacturing and Control (CMC) since 2012.

  • Education: Ph.D., Organic Chemistry, Stockholm University.
  • Other current assignments: Owner of RG Pharma Development.
  • Previous assignments (last five years): Director CMC of Karo Bio AB and QA-associate of Fresenius Kabi AB.
  • Holdings in the Company: 1,000 shares and 124,000 stock options.

thomas

Thomas Plitz

Born 1968. Chief Scientific Officer since 2014.

  • Education: M.Sc. Biology and Ph.D. Immunology and Cell Biology, Technical University of Munich.
  • Other current assignments: –
  • Previous assignments (last five years): Senior Director, R&D Product Strategy Lead of Shire AG and Director, Neurology Global Clinical Development of Merck Serono.
  • Holdings in the Company: 1,500 shares and 150,500 stock options.

_W8A8585LEVFF

Rick Lilley

Born 1957. Chief Regulatory Officer since 2016.

  • Education: B.Sc. Microbiology/Genetics and Ph.D. Molecular Genetics, Queen Mary College, University of London.
  • Other current assignments: –
  • Previous assignments (last five years): SVP, Head of Global Regulatory Affairs, Vertex Pharmaceuticals in Boston, USA. VP, Head of Global Regulatory Affairs, UCB Pharma in Brussels, Belgium.
  • Holdings in the Company:  150,000 performance shares LTIP 2016.

_W8A8344LEVFF

Vincent Metzler

Born 1973. Vice President Commercial Planning & Launch Strategy since 2016.

  • Education: M.Sc. in Chemistry & Biology, Louis Pasteur University in Strasbourg (F). Ph.D. in Molecular Biology, University of Bern.
  • Other current assignments: –
  • Previous assignments (last five years): Head of EMEA Marketing Soliris & Core Member of the Soliris Global Leadership Team, Alexion Pharmaceuticals in Zürich, Switzerland.
  • Holdings in the Company: 10,000 shares and 125,000 performance shares LTIP 2016.